On February 10, 2025 Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, reported its collaboration with OnTargetx R&D Inc. to advance research for its cancer-fighting therapeutic, HT-KIT (Press release, Hoth Therapeutics, FEB 10, 2025, View Source [SID1234650143]). This immunohistochemistry study, conducted in partnership with Charles River Laboratories Montreal ULC, represents a key step in the preclinical development of HT-KIT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study focuses on:

Development and optimization of staining methods for (c-Kit) markers, a critical target in HT-KIT therapeutic mechanism.

Processing and qualitative evaluation of tissue samples by a board-certified pathologist to determine the presence of markers.

Comprehensive reporting and insights to support the continued development of HT-KIT.

"This partnership is instrumental in our efforts to advance HT-KIT, a promising therapeutic aimed at targeting c-Kit in cancer treatments," said Robb Knie, CEO at Hoth Therapeutics. "We are committed to driving innovative solutions that can transform patient care."

The study aligns with Hoth Therapeutics’ mission to accelerate groundbreaking therapies and address unmet medical needs in oncology.

About HT-KIT

HT-KIT is Hoth’s preclinical therapeutic candidate targeting c-Kit, a receptor tyrosine kinase involved in various cancers. This candidate represents a potential advancement in precision oncology therapies.